FL
FLB.F Fluidigm Corporation
- Market cap
- EUR 237M
- P/E
- -
- P/B
- 0.49x
- ROE
- 27.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FLB.F undervalued?
Graham numberThe Graham number of Fluidigm Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fluidigm Corporation fundamental analysis
No fundamental analysis for Fluidigm Corporation yet.
Fluidigm Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fluidigm Corporation
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides So…
Full company profileFluidigm Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fluidigm Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 104M | 102M | 113M | 117M | 138M | 131M | 97.9M | 106M | 91.0M | 85.3M | 80.8M |
| Gross Profit | 58.4M | 52.0M | 61.6M | 64.3M | 83.3M | 69.4M | 37.1M | 50.5M | 44.9M | 42.5M | 43.6M |
| Operating Income | -73.2M | -58.4M | -48.2M | -51.8M | -51.0M | -67.5M | -116M | -63.0M | -87.0M | -93.3M | -33.8M |
| EBITDA | - | -39.4M | -31.0M | -46.6M | -32.6M | -44.3M | -174M | -54.5M | -70.2M | -85.7M | -28.6M |
| Net Income | -76.0M | -60.5M | -59.0M | -64.8M | -53.0M | -59.2M | -190M | -74.7M | -139M | -74.9M | 152M |
| EPS | - | -1.56 | -1.20 | -0.93 | -0.71 | -0.77 | -2.39 | -0.93 | -0.37 | -0.19 | 0.38 |
| Balance Sheet | |||||||||||
| Total Assets | 306M | 287M | 304M | 265M | 325M | 275M | 390M | 323M | 612M | 568M | 635M |
| Total Liabilities | 253M | 256M | 232M | 111M | 186M | 181M | 472M | 471M | 141M | 143M | 79.6M |
| Shareholders' Equity | 53.2M | 30.9M | 72.1M | 154M | 139M | 94.6M | -81.5M | -148M | 472M | 424M | 556M |
| Cash & Short-term Investments | 35.0M | 58.1M | 95.4M | 21.7M | 68.5M | 28.5M | 81.3M | 51.7M | 167M | 121M | 267M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -39.1M | -24.1M | -25.2M | -35.2M | -15.4M | -44.1M | -89.4M | -43.3M | -143M | -74.3M | -84.1M |
| Capital Expenditure | 5.07M | 1.57M | 372K | 2.53M | 12.7M | 13.3M | 3.83M | 2.83M | 8.36M | 8.30M | 1.22M |
| Free Cash Flow | - | -25.7M | -25.6M | -37.7M | -28.1M | -57.3M | -93.2M | -46.1M | -152M | -82.6M | -85.3M |
| Ratios | |||||||||||
| ROE | -142.7% | -195.7% | -81.8% | -42.2% | -38.1% | -62.6% | - | - | -29.4% | -17.7% | 27.3% |
| ROA | -24.8% | -21.1% | -19.4% | -24.5% | -16.3% | -21.5% | -48.7% | -23.1% | -22.7% | -13.2% | 23.9% |
| Net Profit Margin | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% | 187.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fluidigm Corporation dividends
Fluidigm Corporation has not paid dividends in the last 9 fiscal years.
Who owns Fluidigm Corporation
- Insiders 1.84%
- Institutions 74.12%
- Public & others 24.04%
- Shares outstanding 395M
- Free float 187M
Fluidigm Corporation company profile
- Company name
- Fluidigm Corporation
- Ticker
- FLB.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 385
- Fiscal year end
- December
- Address
- 50 Milk Street, Boston, MA, United States, 02109
- Phone
- 650 266 6000
- Website
- standardbio.com
About Fluidigm Corporation
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Fluidigm Corporation management
8- Dr. Michael Egholm Ph.D.President, CEO & Director · born 1963
- Mr. Hanjoon KimChief Financial Officer · born 1971
- Mr. Sean MackaySenior VP & Chief Business Officer · born 1982
- Mr. Jonathan MickelsenVP & Chief Accounting Officer
- John GrazianoVice President of Investor Relations
- Ms. Elizabeth R. JensenChief Human Resources Officer · born 1974
- Mr. Anders DavasSenior Vice President of Global Operations
- Mr. Mike MusgnugSenior VP & Chief Commercial Officer